Drug Report History #136227
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that have changed between versions will be highlighted in yellow, and the changes will be clearly marked as updated.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow, and the change will be clearly marked as updated.
| Field | Version v10-EN | Version v6-EN |
|---|---|---|
| Language | English | English |
| Date Updated | 2021-05-13 (Updated) | 2021-04-05 |
| Drug Identification Number | 02330695 | 02330695 |
| Brand name | ERAXIS | ERAXIS |
| Common or Proper name | ERAXIS | ERAXIS |
| Company Name | PFIZER CANADA ULC | PFIZER CANADA ULC |
| Ingredients | ANIDULAFUNGIN | ANIDULAFUNGIN |
| Strength(s) | 100MG | 100MG |
| Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 30mL vial | 30mL vial |
| ATC code | J02AX | J02AX |
| ATC description | ANTIMYCOTICS FOR SYSTEMIC USE | ANTIMYCOTICS FOR SYSTEMIC USE |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2021-04-01 | 2021-04-01 |
| Estimated end date | (Updated) | 2021-05-14 |
| Actual end date | 2021-05-12 (Updated) | |
| Shortage status | Resolved (Updated) | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | (Updated) | Inventory is on preventative allocation. |
| Health Canada comments |